Ozempic and kidney disease: what the evidence actually shows

What did @healthykidneyinc actually say?

The creator claims a major study, funded by Ozempic's maker, found that semaglutide slows kidney function loss by 24% in people with diabetes and chronic kidney disease. They frame this as good news for diabetic CKD patients specifically, and recommend talking to a doctor about it. They are careful not to overclaim, noting it only applies if you're a candidate and tolerate the drug.

This is a fairly measured take for TikTok. No wild promises, no cure claims, and they correctly identify the diabetic population as the study group. They also mention downstream benefits: blood pressure, cholesterol, and blood sugar control, which tracks with semaglutide's known mechanism. The "24%" figure is the number worth examining closely.

Does the science back this up?

Yes, largely. The FLOW trial (Perkovic et al., 2024, New England Journal of Medicine) is almost certainly the study being referenced. It enrolled over 3,500 patients with type 2 diabetes and CKD, and found semaglutide reduced the risk of a composite kidney outcome by 24% compared to placebo. That composite included sustained 50% decline in eGFR, kidney failure, or death from kidney or cardiovascular causes.

That 24% is a relative risk reduction, not an absolute one. The absolute risk reduction was closer to 5 percentage points over the trial period. That distinction matters enormously when communicating risk to patients, and the creator did not make it. To be fair, most health communicators on social media skip this nuance entirely. The result is still clinically meaningful, and independent nephrologists reviewing the trial called the findings significant. The study was industry-funded by Novo Nordisk, which the creator mentions, but the trial was conducted in an academic setting with rigorous design.

What did they get wrong (or right)?

They got the headline number right. The 24% figure is accurate as a relative risk reduction from the FLOW trial. They also correctly scoped the claim to diabetics with CKD, which matters because that is the only population studied in FLOW. Applying this finding to non-diabetic CKD patients would be a stretch the data does not support yet.

The main problem is the framing of Ozempic as primarily a "weight loss drug" throughout. Semaglutide was originally approved for type 2 diabetes management. Wegovy is the weight loss formulation. In the FLOW trial, the kidney benefit appeared to be partially independent of weight loss or glucose control, suggesting a direct kidney-protective mechanism. Calling it a weight loss drug and then crediting kidney protection to downstream effects like blood sugar and blood pressure improvement misrepresents what the trial actually found. The creators' nephrologist contacts being uncertain in the past is a fair reflection of where the field stood before FLOW published.

What should you actually know?

If you have type 2 diabetes and CKD, the FLOW trial gives your doctor a real, evidence-based reason to consider semaglutide beyond glucose control. The 24% relative risk reduction for serious kidney outcomes is a meaningful number, but your individual absolute risk reduction depends on your baseline kidney function and other risk factors.

A few things the video does not cover: semaglutide carries risks including nausea, vomiting, gastroparesis, and rare cases of acute kidney injury from dehydration, which is particularly relevant in CKD patients who are already volume-sensitive. Dose adjustments are not typically required for CKD, but close monitoring matters. The FDA has not approved semaglutide specifically for CKD protection, so this would be an off-label application in patients without diabetes. The creator's advice to talk to your doctor is not a throwaway line here. It is genuinely the correct step.